300119SZSE
🚨 Material Event

Announcement on Winning the Second Prize of the National Science and Technology Progress Award

✨ AI Summary

Ruipu Bio Pharmaceutical Co., Ltd. and its subsidiary won the second prize of the National Science and Technology Progress Award for their project on avian influenza vaccine innovation and source control. The project developed key technologies and products, including the first full-strain avian influenza inactivated vaccine and a platform for reverse genetics vaccine development. This award highlights the company's R&D strength and contribution to animal disease prevention.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300119

Securities Abbreviation: Ruipu Bio

Announcement No.: 2026-033

Ruipu Bio Pharmaceutical Co., Ltd.

Announcement on Winning the Second Prize of the National Science and Technology Progress Award

The Company and the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Ruipu Bio Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") and its holding subsidiary Guangzhou South China Agricultural University Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as "South China Bio") participated in the project "Innovation and Source Control Key Technologies and Application of Avian Influenza Vaccines," which recently won the second prize of the National Science and Technology Progress Award.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.